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Abstract 
A transgenic animal is an animal in which foreign DNA has been incorporated into its original DNA. The 
generation of transgenic animals is one of the most complex aspects of genetic engineering, both in terms of 
technical difficulty and in the ethical problems that arise. To establish a transgenic animal, foreign DNA 
constructs need to be introduced into the animal’s genome, using recombinant DNA technology, so that the 
construct is stably maintained, expressed and passed on to subsequent generations. The first successful 
transgenic animal was a super mouse since that time the development of transgenic animals and the exploration 
of their applications has been a steady process, although at a slower rate than what was initially expected. DNA 
microinjection, Somatic cell nuclear transfer, Embryonic stem (ES) cells mediated gene transfer and Retrovirus-
mediated gene transfer are the commonly used methods to transfer foreign gene from one species to another. Use 
of transgenic animals will provide solutions for disease model, drug research, food production and improved 
disease resistance. This review summarizes recent research based on the transgenic animal production and their 
potential applications. 
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INTRODUCTION 
Transgenesis is a procedure in which a gene or part of a gene from one individual is incorporated in the genome 
of another one. A transgenic animal is an animal that carries a specific and deliberate modification of its genome 
– analogous to a transgenic plant. The first transgenic experiments in mammals were performed in mice (Gordon 
et al., 1980) afterward rabbits, pigs, sheep and cattle (Hammer et al., 1985, Pursel et al., 1987, Rexroad et al., 
1989, Roschlau et al., 1989). When considered on a global scale, the potential for exploitation of transgenic 
animals would appear to be almost unlimited. Achieving that potential is likely to be a long and difficult process 
in many cases, but the rewards are such that a considerable amount of money and effort has already been 
invested in this area. 
Transgenic farm animals are important in human medicine as sources of biologically active proteins, as 
donors in xenotransplantation (Xenografts from transgenic pig) and for research in cell and gene therapy. 
Typical agricultural applications include: improved carcass composition, lactational performance, wool 
production as well as enhanced disease resistance and reduced environmental impact (Niemann et al., 2005). 
Commercial applications include the preparation of recombinant proteins, protection of animals against disease, 
and introduction of new genetic traits into herds. 
Recent developments in animal gene transfer technique includes DNA microinjection, Somatic cell nuclear 
transfer, Embryonic stem (ES) cells mediated gene transfer and Retrovirus-mediated gene transfer method to 
improve efficiency and gene targeting to improve accuracy (Miao, 2012). But each of techniques has their own 
limitations and most of those techniques are uncertain and have long term effects on transgenic animal 
production. Therefore, the objective of this paper is: to highlight the techniques that are currently applied to 
produce transgenic animals and method of applications and its implications.  
 
TRANSGENIC ANIMALS  
A transgenic animal has been defined as an animal that is altered by the introduction of recombinant DNA 
through human intervention. To establish a transgenic animal, foreign DNA constructs need to be introduced into 
the animal’s genome, using recombinant DNA technology, so that the construct is stably maintained, expressed 
and passed on to subsequent generations. The first transgenic mice were produced in the early 1980s, but it is 
only within the past seven years that transgenic livestock have been produced on a routine basis (Wall, 1996). 
Transgenic animals can be created for a variety of different purposes: to gain knowledge of gene function and 
further decipher the genetic code, study gene control in complex organisms, build genetic disease models, 
improve animal production traits, and produce new animal products (Melo et al., 2007). 
 
Methods for the production of transgenic animals 
Foreign gene to be used in creating the transgenic animal is constructed through a process known as recombinant 
DNA methodology. In this process, desired genes or a piece of DNA to be inserted from another species are cut 
with a restriction enzyme. Isolate plasmids from cloning vector and by using the same enzyme cut plasmids and 
then insert desired DNA into plasmid and then join the two DNA with DNA Ligase (Kinsey and Cooey, 2000). 
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The transgeneis inserted into a vector (which allows it to be amplified to high copy numbers). The vector also 
contains a promoter which allows the inserted foreign DNA to be expressed by the cells of the host animals 
(Anderson and Dowdy, 2005). In generating a transgenic animal, it is desirable that all the cells in the organism 
receive the transgene. The presence of the transgene in the germ cells of the organism will enable the gene to be 
passed on to succeeding generations, and this is essential if the organism is to be useful in the long term. Thus, 
introduction of genes has to be carried out at a very early stage of development, ideally at the single-cell zygote 
stage. The techniques that are currently applied to produce transgenic animals are listed below.  
 
Microinjection Method 
The direct DNA microinjection into the pronuclei of embryos was the first technique which led to regular and 
relatively easy success in mammals. DNA microinjection was successfully used for the first time in 1980 
(Gordon et al., 1980), mouse was the first animal to undergo successful gene transfer. DNA microinjection 
method is based on the injection of a foreign DNA construct into a fertilized oocyte (Figure 1). The construct 
integrates randomly into the host oocyte genome, subsequently the zygote continues embryonic development, the 
embryo is transferred to a foster mother and eventually develops to a transgenic animal. This method has many 
advantages like, exogenous genes are expressed in an efficient manner, the size of the inserted DNA molecule 
has no clear limit and moreover this technique is simple, inexpensive and can be applied to a wide variety of 
species. However, as microinjection has several significant shortcomings including low efficiency, random 
integration and variable expression patterns related to the site of integration – research has focused on alternative 
methodologies for improving efficiency of generating transgenic livestock (Robl et al., 2007).  
 
Figure 1. DNA micro-injection 
Somatic cell nuclear transfer 
The method of choice nowadays for the production of transgenic animals is somatic cell nuclear transfer 
(SCNT). In genetics and developmental biology, somatic cell nuclear transfer (SCNT) is a laboratory technique 
for creating a viable embryo from a body cell and an egg cell. The entire method is based on the following 
protocol: oocytes from a donor animal are enucleated, i.e. their nucleus containing the genome is removed. 
Subsequently a donor nucleus is injected into the enucleated oocyte, and the cells are fused by electrofusion. 
Following fusion, the oocyte is activated by chemical or mechanical means to initiate embryonic development, 
and the resulting embryo is transferred to a foster mother (Hodges and Stice, 2003). The donor nuclei can be 
derived from either somatic cells or ES cells that have been subjected to targeted genetic manipulation prior to 
injection into the oocyst. Somatic cell transfer may be used to generate multiple copies of genetically elite farm 
animals, to produce transgenic animals for pharmaceutical protein production or xeno-transplantation (Wilmut et 
al., 1997; Polejaeva et al., 2000) or to preserve endangered species. Dolly the Sheep, famous for being the first 
successfully cloned mammal was created using this process (Li et al., 2009). 
 
Embryonic stem (ES) cells mediated gene transfer 
Embryonic stem cells, as the name suggests, are derived from embryos at a very early stage (the blastula), and 
have achieved major consideration in recent years in the field of medicine, agriculture and biomedical research 
due to their unique property of pluripotency. Pluripotency is the ability of these cells to differentiate to any of the 
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cell types and tissues found in the adult organism. ES cells can be grown in culture for many passages and can be 
subjected to transformation with transgene constructs, resulting in modifications of their genome. The constructs 
used not only permit the selection of successfully transformed cells, but also allow gene targeting to be 
accomplished. Thus, genes can be specifically introduced, replaced or deleted (so-called knock-ins and knock-
outs). Transformed ES cells are re-introduced into the blastocoel cavity of an embryo, where they integrate and 
produce a mosaic (chimaeric) animal, i.e. an animal that is made up of transformed and non-transformed cells. 
Possibly, the chimaeric animal carries the transgene in the germ line; in this case, it is possible to obtain 
completely homozygous transgenic animals through selective breeding (Figure 2). This technique, mainly 
through the feature of gene targeting, allows a broad variety of genetic modifications to be introduced. For many 
years, several laboratories worldwide have tried to produce ES cells from farm animals, and although some 
success has been claimed, no robust and reproducible method has been published. Indeed, even in mice the 
production of ES cells is a costly and labour-intensive technology (Melo et al., 2007). 
 
Figure 2. Embryonic stem (ES) cells mediated gene transfer (A) and Somatic cell nuclear transfer (B). 
 
Retrovirus-mediated gene transfer 
Transgenesis may also be accomplished by employing virus-derived vectors, namely vectors based on the 
retrovirus-class of lentiviruses (Whitelaw et al., 2008). Retrovirus is single stranded RNA virus which upon 
transfection gets converted to double strand DNA and integrates into the host genome (Eglitis et al., 1988). 
Genes that are essential for viral replication are deleted from the viral genome, maintaining only the capacity for 
integration of the viral genome into the host genome. Parts of the vector that were occupied by viral genes can 
then be replaced by the transgene of interest – an approach analogous to the modification of the A. tumefaciens 
Ti-plasmid. Viruses carrying the modified vector are then produced in vitro and subsequently injected into the 
perivitelline space of the zygote (or an unfertilized oocyte), resulting in infection of the zygote and integration of 
the viral genome into the host genome. Transgenesis rates reaching up to 100 percent of injected embryos have 
been described (Park, 2007). Major drawbacks of this method are a limited transgene size and random transgene 
integration. The maximal transgene size is 8 kb, which is rather low compared with other techniques. Random 
and possibly multiple transgene integration may lead to position effects, disturbance of the host genome and dose 
effects, as is the case with pronuclear injection. Solving these problems holds great promise for the further 
development and application of lentiviral vectors.  
 
Application of transgenic animals 
Transgenic animals for food production 
Engineering transgenic animals with an application in food production focuses mainly on improved meat 
production, improved carcass quality and enhanced milk production. Milk is a complex biological fluid and has a 
high importance for contributing to the nutrition of many societies (Melo et al., 2007). The major goals for 
transgenic animal development concerning milk production are increased milk production, higher nutrient 
content or milk containing novel substances. Most milk proteins (circa 80 percent) belong to the caseins, and 
transgenic cattle were created that contain extra copies of casein genes. This resulted in elevated casein protein 
levels in milk (Brophy et al., 2003). Another milk application that is being investigated is the production of milk 
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with no lactose (milk sugar) present, since approximately 70 percent of the world population cannot metabolize 
lactose and thus cannot consume dairy products. Engineering milk with novel properties, e.g. milk containing the 
immune-stimulating human protein lactoferrin, is a further approach. Many other additives, e.g. different growth 
hormones or substances that stimulate health and development, have been proposed for overexpression in milk 
and thus possibly contribute to growth and health of developing offspring.  
In pigs, the transfer of the bovine a-lactalbumin gene led to increased milk production, resulting in faster 
piglet growth and survival rate. One of the first reports with relevance for enhanced meat production was the 
article about the first transgenic mice, expressing rat growth hormone and showing increased body size and mass. 
However, transferring this approach to pigs initially did not yield promising results. Nevertheless, pigs showing 
increased muscle weight gain and feed efficiency by introducing porcine growth hormone or human insulin-like 
growth factor have been created (Niemann et al., 2005). Furthermore, pigs expressing the enzyme phytase in 
their salivary glands have been created: these animals can metabolise the phosphor present as phytic acid in corn 
and soy products, thus needing less phosphor as feed additives and releasing less phosphor with their manure, 
reducing the environmental impact of pig farming (Haefner et al., 2005). Experiments in cattle are focusing on 
the myostatin gene, a negative regulator of muscle mass, resulting in a high increase in muscle mass in animals 
with a myostatin mutation or deletion. Transgenesis is also employed for fish; injection of embryos with 
constructs containing either the bovine or Chinook salmon growth hormone has been reported, with the aim of 
improving fish growth in general and especially under adverse conditions, e.g. low water temperatures. This has 
resulted in an up to 5-11 fold increase in weight after one year of growth for transgenic salmon and 30-40 
percent increased growth of transgenic catfish (Wheeler, 2007). All these studies demonstrate the fundamental 
feasibility of applying transgenesis to agricultural animals for improved food production, but so far no transgenic 
food producing animal has been released for commercial use. In addition to the research and development 
necessary for the establishment of a transgenic animal, there are several other factors that strongly influence the 
use of transgenic animals for food production. Among these are considerations concerning the economic 
practicability, social acceptance of transgenic food and, possibly most important, regulations concerning the 
approval of GMOs and derived products.  
Regulatory authorities need to consider three factors: Safety of the food product for human consumption; 
Environmental impact of the genetically modified animals and welfare of the animals. These factors need to be 
considered on a case-to-case approach for every new transgenic animal or product that has been obtained using 
GMOs. In principle, this safety investigation is identical to the safety regulations and procedures that apply for 
transgenic plants. 
 
Transgenic animals for production of human therapeutics 
One major application of animal transgenesis nowadays is the production of pharmaceutical products, also 
known as animal pharming. The costs for producing transgenic animals are high, but since the pharmaceutical 
industry is a billion-dollar market the input is likely to be a feasible and economically worthwhile investment 
(Sullivan et al., 2008). Since many human proteins cannot be produced in microorganisms and production in cell 
culture is often labour-intensive with low yields, the production of biopharmaceuticals in transgenic animal 
bioreactors is an attractive alternative (Kind and Schnieke, 2008). Furthermore, many human proteins cannot be 
produced in micro-organisms, since they lack post-translational modification mechanisms that are essential for 
the correct function of many human proteins.  
Pharmaceutical proteins or other compounds can be produced in a variety of body fluids, including milk, 
urine, blood, saliva, chicken egg white and seminal fluid, depending on the use of tissue-specific promoters 
(Houdebine, 2009). Nevertheless, milk is the preferred medium due to its large production volume. Furthermore, 
it has been shown that the mammary glands can produce up to 2 g of recombinant protein per litre of milk; 
assuming average protein expression and purification levels, only relatively small herds of transgenic animals 
would be required to supply the world market with a specific recombinant protein (e.g. 100 transgenic goats for 
the production of 100 kg monoclonal antibodies required per year (Melo et al., 2007). In Table 1, biomolecules 
expressed in mammary glands and their anticipated applications are listed: 
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Table 1. Pharmaceuticals produced by transgenic animals 
 
Another advantage of biopharmaceutical production in transgenic animals is the reduced risk of transmitting 
diseases, compared with human-derived material. Several cases are known where hundreds of patients were 
infected with HIV, Hepatitis C or Creutzfeld-Jakob-disease following treatment with human-derived 
pharmaceuticals. Of course, animal-derived material needs to be subjected to a thorough purification procedure 
to exclude transmission of animal diseases (zoonoses) or contamination with animal DNA or protein that might 
induce an immune reaction. Nevertheless, the development of transgenic animals that secrete high contents of 
the desired product in their milk, and the subsequent development of an effective and high-yield purification 
protocol to get rid of contaminating proteins, requires a lot of knowledge and financial and intellectual input. So 
far, only GTC Biotherapeutics Antithrombin III has been approved for the united States market and is sold under 
the name of ATryn (FdA, 2009). Furthermore, many potential target proteins as well as the technologies to 
develop a transgenic animal are covered by patents and intellectual property rights, thus only a small number of 
proteins are being investigated by a small number of pharmaceutical companies at the moment (Kind and 
Schnieke, 2007). 
A particularly promising approach is the development of transgenic animals that express human polyclonal 
antibodies. Antibodies are the fastest growing set of new biopharmaceuticals, for therapeutic use in cancer, 
autoimmune diseases, infections, transplantations, biodefence and immune deficiencies. Currently all approved 
therapeutic antibodies are produced by cell culture techniques. 
The possibilities for the production of polyclonal human antibodies in transgenic cattle are currently being 
investigated; such antibodies would mimic the natural human immune response to a pathogen. Cattle would be 
especially suited for this purpose, since the total amount of antibodies in an adult animal is approximately 1 kg. 
One approach towards this end is the use of artificial chromosomes to transfer the human antibody genes to the 
target animal (Kuroiwa et al., 2002). Concomitantly, the endogenous antibody genes of the animal are knocked 
out to prevent their expression and thus allow purification of human antibodies without contaminating bovine 
antibodies. To obtain human polyclonal antibody sera from the animal, the animal would need to be immunized 
with a vaccine containing the pathogen of interest, e.g. a bacterium or a virus. Subsequently, the animal would 
build up an immune response and express the human antibodies directed against that pathogen. These antibodies 
could subsequently be extracted and purified from the animal’s blood plasma and used to treat humans suffering 
from an infection with that particular pathogen. This perspective for a quick availability of large amounts of 
human antibody sera targeted against a certain pathogen or disease agent has raised speculations about a 
transformation of medicine similar to the introduction of antibiotics in the 1940s and 50s (Kind and Schnieke, 
2007). Similar approaches, based on the same methodology, are being pursued for the use of plants as 
bioreactors for the production of medically valuable proteins and small-molecule drugs (Twyman et al., 2005). 
 
Transgenic animals for improved disease resistance 
Resistance or susceptibility to diseases and the immune response typically depend on a variety of genes, but 
identification of some key genes has brought up the possibility of gene transfer to target important and specific 
aspects of the immune system (Niemann et al., 2005). Diseases that are under investigation, by either 
introducing resistance genes or removing susceptibility genes, include bovine spongiform encephalopathy (BSe), 
brucellosis, other viral or bacterial infections, parasitic organisms, and intrinsic genetic disorders. 
one often-cited example is resistance against mastitis: mastitis is a bacterial infection of the bovine 
mammary gland, leading to decreased productivity and milk contamination. Transgenic cattle have been 
produced that secrete the small protein lyostaphin in their milk, which is a potent inhibitor of Staphylococcus 
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aureus (S. aureus), the bacterium responsible for the majority of mastitis cases. According to first trials, the 
transgenic cows are resistant to S. aureus – mediated mastitis (Donovan et al., 2005). Further approaches of 
animal transgenics target animal reproductive performance and prolificacy, development of organs for 
transplantations (xenotransplantation) that do not evoke a rejection response, or improvement of animal fibre and 
wool. 
 
CONCLUSION  
The establishment of stable transgenic animals implies that the foreign DNA is present in gametes or one-cell 
embryos to allow its transmission to progeny. The techniques that are currently applied to produce transgenic 
animals include DNA microinjection, Somatic cell nuclear transfer, Embryonic stem (ES) cells mediated gene 
transfer and Retrovirus-mediated gene transfer. In coming years transgenic animals will play a significant role 
for disease model, drug research, food production and improved disease resistance. The regulatory aspects and 
ethics should be given due consideration while using transgenic animals. As transgenic animals become more 
mainstream, a small yet growing portion of the animal production industry. It will shift its operations from 
farming livestock for food production, to transgenic animals for pharmaceutical production. The world market is 
growing for human pharmaceutical products. Producing transgenic animals is still relatively expensive. However, 
costs are trending down and transgenic animals have certain advantages over traditional laboratory methods for 
producing human proteins. More commercial use of transgenic animals in food production is also likely. 
Regulators will need to review existing policies and guidelines regarding transgenic animals. Regulatory 
authorities need to consider three factors: safety of the food product for human consumption, environmental 
impact of the genetically modified animals and welfare of the animals. Transgenic technologies will ensure that 
further research and analyses will be demanded by animal producers, regulators, environmentalists, and the 
general public. 
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